⌕

Cboe Global Markets (CBOE) vs Royalty Pharma (RPRX)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
63
Cboe Global Markets Inc.
$375.42 · $39B · as of last close
Fastest growerStrongest balance sheetBest returns
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is growth.

#2 FIT
59
Royalty Pharma plc
$69.31 · $40B · as of last close
Best incomeCalmest rideStreet favorite
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is dividend & income.

CBOE barely leads (63/100 vs RPRX 59) under a balanced style, mostly on growth. But RPRX wins on dividend & income, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorCBOERPRX
Overall fit score
weighted for your balanced goal
✓ 63
59
Valuation
Cheaper for what you get
1×
✓ P/E 27 · EV/EBITDA 18.6
P/E trailing
32
✓ P/E 57
P/E trailing
32
Growth
Revenue & earnings momentum
1×
✓ —
70
—
14
Profitability & quality
Margins & return on capital
1×
✓ Net 28% · ROIC 19%
TTM through Sep 30, 2026
72
Net 45% · ROIC 8%
TTM through Sep 30, 2026
68
Total return
Share-price change with dividends reinvested
1×
✓ 5Y +25%/yr
92
5Y +15%/yr
77
Risk (calm = better)
Volatility & drawdown
1×
β −0.3 · DD −37%
88
✓ β 0.3 · DD −42%
95
Balance sheet†
Debt vs cash cushion
1×
✓ Net debt/EBITDA −0.6×
TTM through Sep 30, 2026
62
Current ratio 1.29
Sep 30, 2026 balance sheet
26
Dividend & income
Cash paid to you
1×
0.80% yield· A+
24
✓ 1.36% yield· C
92
Analyst sentiment
Forward EPS growth (consensus)
1×
Est EPS +8%/yr · 11 analysts
62
✓ Est EPS +10%/yr · 4 analysts
64
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ CBOE■ RPRX
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
CBOE−37%−0.3025%5Y
RPRX−42%0.2524%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on growth: — (score 70).

▲ Leads on balance sheet (score 62). Net debt/EBITDA −0.6× is one of the 5 inputs.

BEAR CASE

▼ Weakest on dividend & income: 0.80% yield (score 24).

▼ Weakest on risk (calm = better): β −0.3 · DD −37% (score 88).

BULL CASE

▲ Leads on dividend & income: 1.36% yield (score 92).

▲ Leads on risk (calm = better): β 0.3 · DD −42% (score 95).

BEAR CASE

▼ Weakest on growth: — (score 14).

▼ Weakest on balance sheet (score 26). Current ratio 1.29 is one of the 5 inputs.

WHAT COULD CHANGE THE SCORE
Dividend & incomeCurrently 24/100 (0.80% yield). Taking it to 100 would lift the balanced score by 9 points, the biggest single move available.
ValuationCurrently 32/100 (P/E 27 · EV/EBITDA 18.6). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
GrowthCurrently 14/100 (—). Taking it to 100 would lift the balanced score by 10 points, the biggest single move available.
Balance sheetCurrently 26/100 (Current ratio 1.29). Taking it to 100 would lift the balanced score by 9 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.